AbbVie VP joins UCB Pharma
January 25, 2016Manufacturing and Production, Research and Development, Sales and Marketing Pascale Richetta, UCB, UCB Pharma
Pascale Richetta will join the UCB as its new head of the bone therapy patient value unit as from February …
Cancer Research UK appoints Professor Sir Bruce Ponder as trustee
January 25, 2016Research and Development Cancer Research UK, Professor Sir Bruce Ponder
Cancer Research UK has appointed Professor Sir Bruce Ponder as a trustee. Ponder is emeritus professor of oncology at Cambridge …
Amgen earns first Japanese nod for PCSK9 inhibitor
January 25, 2016Sales and Marketing Amgen, Astellas, Japan, PCSK9 inhibitor, Repatha, evolocumab, high cholesterol
The Japanese Ministry of Health, Labour and Welfare has approved Amgen’s cholesterol-lowering medication Repatha, in a joint venture between Amgen …
The case for leaders with scientific acumen in pharma
January 25, 2016Medical Communications, Research and Development research and development
Pharmaceutical companies are currently undergoing fundamental, disruptive changes to conventional research and development models. This is in an attempt to …
Big pharma and UK universities launch £40m innovation fund
January 25, 2016Research and Development, Sales and Marketing Apollo, AstraZeneca, GSK, GlaxoSmithKline, Johnson & Johson, UCL, University College London, University of Cambridge, collaboration, imperial college london, joint venture
A consortium of big pharma companies and university with world-leading medical research facilities is to invest £40 million, to “significantly …
Researchers raise TPP legislation concerns
January 25, 2016Manufacturing and Production, Sales and Marketing Legislation, Trans-Pacific Partnership, tpp, trade agreement
Academics have warned that global trade regulations under consideration by the US and other countries could prevent access to medicines …
FDA approves new uses for BMS’ Opdivo/Yervoy cancer combo
January 25, 2016Sales and Marketing BMS, Bristol-Myers Squibb, Yervoy, ipilimumabm melanoma, nivolumab, opdivo, skin cancer
The FDA has granted Bristol Myers Squibb an expanded indication for its two-cancer drug regimen Opdivo and Yervoy, to treat …
AbbVie and MD Anderson in cancer research partnership
January 25, 2016Research and Development, Sales and Marketing AbbVie, MD Anderson Cancer Centre, immuno-oncology
AbbVie has announced a new partnership with The University of Texas MD Anderson Cancer Centre, using its immunotherapy platform to …
Patients sue J&J for $800m for ‘hiding antibiotic side effects’
January 22, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Janssen, Johnson and Johnson, Levaquin, Margaret Hamburg, lawsuit, levofloxacin
Six users of Johnson & Johnson’s antibiotic Levaquin are to sue the company for up to $870 million, claiming the …
California hospital becomes first to prescribe digital pill
January 22, 2016Medical Communications california, digital health, digital pill, ingestible pill, proteus
Proteus Digital Health, the first company to have a ‘digital pill’ approved by the FDA, has signed its first deal …
FDA approves new Kyprolis combo for multiple myeloma
January 22, 2016Medical Communications, Sales and Marketing Amgen, FDA, Kyprolis, carfilzomib, multiple myeloma, myeloma
Amgen’s Kyprolis has been given another endorsement by the FDA as a multiple myeloma treatment – its second in six …
Merck appoints Jessie English to lead discovery team
January 22, 2016Research and Development Jessie English, Merck
Merck has appointed Jessie English as the new vice president of discovery, translational innovation platform immuno-oncology, effective February 16, 2016. …
NICE ‘yes’ for BMS skin cancer drug Opdivo
January 22, 2016Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, NICE, melanoma, nivolumab, opdivo, skin cancer
NICE has approved Bristol-Myers Squibb’s skin cancer immunotherapy Opdivo (nivolumab) in final draft guidance as monotherapy for NHS patients in England …
Martin Shkreli subpoenaed in US to testify over drug pricing
January 21, 2016Medical Communications, Sales and Marketing Daraprim, Howard Schiller, Martin Shkreli, Valeant, turing
Former pharma chief exec Martin Shkreli has been issued with a subpoena by the US House of representatives, compelling him …
UK Pfizer boss criticised for NHS conflict of interest
January 21, 2016Erik Nordkamp, Keep Our NHS Public, King's College Hospitals NHS Trsut, NHS, Pfizer, conflict of interest, privitisation
Anti-privatisation campaigners have called on a London NHS hospital trust to revoke its decision to appoint the head of Pfizer …
AbbVie/Roche’s venetoclax bags FDA Breakthrough Therapy Designation
January 21, 2016Sales and Marketing AbbVie, Breakthrough Therapy Designation, FDA, Roche, venetoclax
AbbVie and Roche’s cancer drug venetoclax has been granted Breakthrough Therapy Designation by the FDA in combination with rituximab for …
GSK ‘in discussions’ over $1 billion tech deal with Qualcomm
January 21, 2016Medical Communications GSK, beyond the pill, digital pharma, joint venture, qualcomm
GlaxoSmithKline and telecoms giant Qualcomm are reportedly discussing a joint venture agreement worth as much as $1 billion, as the …
Five charged in US for scheme to steal GSK secrets
January 21, 2016Research and Development China, GSK, employee theft, trade secrets
Five people have been charged in the US for a scheme to steal secrets from British drugmaker GlaxoSmithKline and then …
Pharma leads global call for action on antimicrobial resistance
January 21, 2016Manufacturing and Production, Research and Development Davos, Lord Jim O'Neill, Review on antimicrobial resistance, World Economic Forum, antibiotic resistance, antimicrobial resistance
More than 70 leading international pharmaceutical and biotechnology companies, as well as industry associations, have come together to call for …
MSD and GAVI agree Ebola vaccine deal
January 20, 2016Manufacturing and Production, Research and Development Ebola, GAVI, MSD, WHO
MSD and the global vaccine alliance Gavi have agreed a deal to provide 300,000 dosesof an Ebola virus vaccine, to …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
